Iovance Biotherapeutics, Inc. — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; filed February 25, 2020. The filing also reports unaudited quarterly results, including Q4 2019. Iovance is a clinical-stage biotechnology company developing patient-specific tumor-infiltrating lymphocyte (TIL) therapies and had no products approved for sale.
Financial performance and position
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $166.0 million | $99.8 million |
| General and administrative expense | $40.8 million | $28.4 million |
| Operating loss | $206.9 million | $128.3 million |
| Net loss | $197.6 million | $123.6 million |
| Net loss per share, basic and diluted | $1.59 | $1.27 |
| Cash used in operating activities | $158.9 million | $101.2 million |
Q4 2019 revenue was $0; net loss was $63.6 million, or $0.50 per share, compared with a $32.6 million loss, or $0.27 per share, in Q4 2018. No meaningful operating margin is available because the company had no revenue.
At year-end, cash and cash equivalents were $14.0 million, short-term investments $293.1 million, and restricted cash $5.5 million. Working capital was $277.4 million, total assets $344.7 million, total liabilities $45.7 million, and stockholders’ equity $299.0 million. The filing reports no conventional borrowings; liabilities chiefly include accounts payable, accruals and lease obligations. Accumulated deficit was $570.6 million. Management said available funds were expected to cover anticipated operating expenses and capital expenditures for at least 12 months from the filing date.
Changes versus comparable periods
- Annual net loss increased $74.0 million, or 60%, as research, clinical-trial, manufacturing and corporate spending expanded.
- R&D expense rose 66%, principally from increased manufacturing costs ($27.4 million), clinical-trial costs ($20.3 million), and payroll and related costs ($12.6 million).
- G&A expense rose 44%, reflecting higher payroll, stock compensation, intellectual-property legal costs and commercialization market research.
- Operating cash use increased by $57.6 million. Year-end cash and short-term investments together declined from $468.5 million in 2018 to $307.1 million in 2019.
- Weighted-average common shares increased to 124.3 million from 97.3 million, reflecting prior equity offerings and other share issuance. The company raised no public-offering proceeds in 2019; option exercises provided $6.4 million.
Business, outlook and material risks
- Lead programs: Lifileucel is in a Phase 2 pivotal program for advanced melanoma; LN-145 is in a Phase 2 pivotal program for recurrent, metastatic or persistent cervical cancer. The company reported preliminary results: lifileucel Cohort 2 had a 36% investigator-assessed response rate in 66 patients; LN-145 had a 44% response rate in 27 patients. These are interim clinical findings, not established approval or commercial outcomes.
- Regulatory plans: The company planned to submit a lifileucel BLA in late 2020, incorporating Cohort 4 results, and planned an LN-145 BLA by the end of 2020 after further FDA consultation. It expected to complete enrollment in cervical cancer pivotal Cohort 1 around mid-2020. Management described a potential 2021 commercial launch if products are approved. These plans depend on trial results, FDA review and manufacturing readiness.
- Development pipeline: Trials also cover head and neck cancer, lung cancer and PBL therapy for CLL/SLL. IOV-CLL-01 was cleared to proceed in November 2019. The company reported receiving FDA Fast Track and Breakthrough Therapy designations for LN-145 and Fast Track and RMAT designations for lifileucel; designations do not assure approval.
- Manufacturing and investment: Iovance relied on contract manufacturers and was building a commercial-scale Philadelphia facility. It estimated $75–$85 million of equipment and construction spending over three years, in addition to significant ongoing clinical and manufacturing costs. Manufacturing scale-up, quality, comparability, capacity, timing and cost are key execution risks.
- Funding and dilution: The company expected continued significant losses and negative operating cash flows and may need additional financing. Future equity issuance could dilute shareholders; debt or partnership financing could impose other constraints or require rights concessions.
- Other risks and contingencies: Clinical efficacy and safety may not be confirmed; FDA requirements or timelines may change; patient enrollment, reimbursement, competition and commercial adoption are uncertain. The filing describes unresolved derivative, Solomon Capital and former-employee litigation, among other matters, for which potential losses were not estimable in certain cases. A proposed derivative-case settlement awaited court approval. The prior securities class action settlement was paid by the insurer. The filing also identifies an SEC cease-and-desist order related to past stock promotions and notes potential constraints on future capital raising and communications.
- Accounting and unusual items: Adoption of lease accounting guidance in 2019 added operating lease right-of-use assets and liabilities; the auditor identified lease valuation and incremental borrowing-rate judgments as a critical audit matter. A 2019 settlement included cancellation of 32,500 shares and a $0.3 million gain.
Important facts for investors to verify
- Whether pivotal-trial results—particularly independent-review response assessments, durability and safety—support the planned BLAs and withstand FDA review.
- Whether the company met or revised its stated 2020 enrollment and filing plans, and the actual timing and requirements for any FDA submissions.
- Current cash runway, subsequent cash burn, facility spending and financing needs; the runway statement was management’s estimate as of the 2020 filing date.
- Progress, validation, capacity, cost and regulatory readiness of the Philadelphia facility and third-party manufacturing network.
- Status and financial exposure of the pending litigation and any changes to the SEC-related restrictions or capital-raising options.